Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

IT4B-ALL

Financiado

Therapeutic immunotherapy targeting NG2 and CD22 antigens for MLL rearranged and...

Therapeutic immunotherapy targeting NG2 and CD22 antigens for MLL rearranged and MLL germline B cell Acute Lymphoblastic Leukemia B-ALL is the commonest cancer of childhood. There remain childhood B-ALL subgroups with dismal prognosis such as infant B-ALL and B-ALL carrying MLL rearrangements (MLLr). In addition, the prognosis of adult B-ALL is worse, and re... ver más

30/06/2020

FUNDACIO INSTITUT...

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEM... Actividades de investigación asociacion

TRL 4-5 | 50K€

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-06-30

ERC-2018-PoC: ERC Proof of Concept Grant

I+D

Cerrada hace 6 años

0% 100% 100%

2 Participantes

FUNDACIO INSTITUT DE RECERCA...

150.00K€ | Lider

ALBIRAL DISPLAY SOLUTIONS

117.00K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2016-80481-R INMUNOTERAPIA ADOPTIVA CON CELULAS T CAR-NG2 PARA LA LEUCEMI... 327K€ Cerrado

PID2019-108160RB-I00 TIM3, UNA NUEVA Y PROMETEDORA DIANA INMUNOTERAPEUTICA EN LEU... 339K€ Cerrado

BES-2017-080380 INMUNOTERAPIA ADOPTIVA CON CELULAS T CAR-NG2 PARA LA LEUCEMI... 93K€ Cerrado

BiTE-CAR CD22/CD19 dual redirection Dual targeting of CD22 and CD19 w... 150K€ Cerrado

CARLY Development and characterization of a novel CAR T-cell thera... 226K€ Cerrado

BES-2014-068419 MODULADORES Y EFECTORES DE LA SEÑALIZACION POR NOTCH1 EN EL... 88K€ Cerrado

Duración del proyecto: 21 meses Fecha Inicio: 2018-09-17
Fecha Fin: 2020-06-30

Líder del proyecto

FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEM... Actividades de investigación asociacion

TRL 4-5 | 50K€

Presupuesto del proyecto 150K€

Descripción del proyecto B-ALL is the commonest cancer of childhood. There remain childhood B-ALL subgroups with dismal prognosis such as infant B-ALL and B-ALL carrying MLL rearrangements (MLLr). In addition, the prognosis of adult B-ALL is worse, and refractory/relapse (R/R) B-ALL remains dismal. CD19-targeted immunotherapies have emerged as promising therapeutic approaches for R/R B-ALL. CD19 CAR T-cells have shown impressive efficacy in R/R B-ALL. However, relatively rapid relapses are frequently observed, a proportion of them losing CD19 expression upon CAR19 T-cell therapy due to massive antigen pressure over CD19, resulting in a myeloid lineage switch in MLLr B-ALL, or the selection of CD19-/CD34+ preleukemic progenitors. Further CD19-targeted therapy is thus ineffectual for CD19neg R/R B-ALL. Our overarching goal is to provide novel therapeutic options for (R/R) B-ALL.Targeting surface antigens whose expression, opposite to CD19, are commonly retained at relapse is a valid strategy to circumvent the loss of CD19 found in (R/R) B-ALL after CD19-targeted therapies. Recent work funded by my ERC-2014-CoG has identified NG2 and CD22 as key antigens to be targeted in (R/R) B-ALL. First, both antigens are retained in CD19neg R/R B-ALL. Second, NG2 is solely expressed in MLLr B-ALL, and is associated with CNS infiltration, aggressiveness and glucocorticoid resistance. Third, CD22 is a pan-B marker expressed developmentally earlier than CD19, and CD34+CD22+CD19- cells may represent pre-malignant progenitors escaping the CD19-targeted pressure. These results have just been protected by a European Patent (EPI173825514), and are the proof-of-principle demonstration of NG2 & CD22 representing promising immunotherapeutic targets, when combined with CD19 for both MLLr & MLL-germline B-ALL, respectively. Here we propose to consolidate preclinical work and GMP production of anti-NG2 monoclonal antibody and NG2/CD19 and CD22/CD19 CAR T-cells to launch a PhaseI academic clinical trial for R/R B-ALL

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores